Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly’s Lebrikizumab Atopic Dermatitis Monotherapy Trials
The Pharma Data
JUNE 7, 2022
. “We look forward to providing an important new medicine and helping patients find the relief they so desperately seek from the varied and debilitating symptoms of this disease, contingent upon FDA approval.” Almirall also plans to submit these results this year to the European Medicines Agency (EMA) for authorization.
Let's personalize your content